TNAXEarnings•globenewswire•
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Sentiment:Negative (20)
Summary
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 13, 2025 by globenewswire